Physician profile
Uri Napchan
NPI 1710045844
$205,960.15
in general payments reported to CMS, 2019-2025
19 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $45K · 2021: $29K · 2022: $33K · 2023: $13K · 2024: $28K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,800 · Consulting Fee: $6,670 · Food and Beverage: $5,260 · Travel and Lodging: $1,907 · Honoraria: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,762.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,800.00 |
| Consulting Fee | $6,670.00 |
| Food and Beverage | $5,259.68 |
| Travel and Lodging | $1,906.58 |
| Honoraria | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58,093.77 | 2021-2025 | |
| Lilly USA, LLC | $56,048.00 | 2019-2022 | |
| Allergan, INC. | $27,134.74 | 2019-2022 | |
| Amgen INC. | $25,463.21 | 2019-2022 | |
| Eisai INC. | $16,488.37 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $15,858.37 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $6,224.74 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $300.15 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Avanir Pharmaceuticals, INC. | $48.41 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $24.95 | 2024 | |
| Ironshore Pharmaceuticals INC. | $24.61 | 2024 | |
| Upsher-Smith Laboratories LLC | $23.22 | 2021 | |
| Boston Scientific Corporation | $22.12 | 2023 | |
| Acadia Pharmaceuticals INC | $20.37 | 2025 | Nuplazid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $16.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.81 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.76 | 2019 | |
| Currax Pharmaceuticals LLC | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uri Napchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.